Pharmacy Times
SEPTEMBER 12, 2024
Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.
STAT
SEPTEMBER 12, 2024
Disease investigators have not been able to determine how a person in Missouri with no known exposures to animals or poultry became infected with an H5 bird flu virus, the principal deputy director of the Centers for Disease Control and Prevention said Thursday. But Nirav Shah said the ongoing investigation has turned up no evidence of onward spread of the virus, suggesting this case may turn out to be a one-off infection that defies explanation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
SEPTEMBER 12, 2024
Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.
STAT
SEPTEMBER 12, 2024
After his son Michael was diagnosed with a devastating, ultra-rare disease in 2019, Terry Pirovolakis dedicated himself to eradicating it. Pirovolakis, a Canadian IT director, recruited academics and raised $3 million to design a gene therapy. He got Michael treated, an intervention that seems to have helped the 6-year-old stand on his heels for the first time and slow the course of a disease that can be severely cognitively and physically disabling.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
SEPTEMBER 12, 2024
Industry experts and physicians conducted a state-by-state breakdown of vaccination statistics for children and teenagers as well as adults and elderly individuals.
STAT
SEPTEMBER 12, 2024
After years of dabbling in hearing health, Apple earlier this week went all-in, announcing that AirPods Pro, the tech giant’s top wireless earbuds, will soon double as hearing aids for people with milder forms of hearing loss. Apple’s redoubled effort on hearing also includes software to test a person’s hearing and to customize the output of the hearing aid.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
SEPTEMBER 12, 2024
Gilead Sciences is no stranger to making history in HIV. | In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.
STAT
SEPTEMBER 12, 2024
Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate. Stephen Hoge, Moderna’s president, in an interview pointed to Moderna’s “massively productive R&D engine,” citing nine medicines in the late stages of development that he says could be filed with regulators over t
Drug Topics
SEPTEMBER 12, 2024
Findings could inform future clinical practices on the treatment of DED for the more than 400 million people worldwide with the condition.
STAT
SEPTEMBER 12, 2024
In a rare display of bipartisan agreement, Congress is getting serious about addressing China’s influence in key industries. This spring’s “TikTok ban” is the most obvious example of this effort. Legislation currently under debate would extend these same principles to the life sciences sector, with major implications and opportunities for the country.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
SEPTEMBER 12, 2024
Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.
STAT
SEPTEMBER 12, 2024
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit’s success? Why can’t Moderna turn a profit? And should we be giving weight loss drugs to kids? We talk about all that and more on this week’s episode of “The Readout LOUD.
Pharmacy Times
SEPTEMBER 12, 2024
An overview of the potential treatment strategies for patients were presented at the 2024 World Conference on Lung Cancer.
STAT
SEPTEMBER 12, 2024
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I ate three dozen oysters last Saturday while taking a tour of the Island Creek Oyster Farm in Duxbury, Mass. AMA.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
SEPTEMBER 12, 2024
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. Yet company CEO Hervé Hoppenot views the antibody molecule not necessarily as a major revenue driver but as an aide to the company’s oncology pipeline.
Fierce Healthcare
SEPTEMBER 12, 2024
Lehigh Valley Health Network has come to a $65 million class-action lawsuit settlement stemming from a 2023 ransomware attack that led to hundreds of patients’ nude medical record photos being post | After the nonprofit system refused to meet a ransomware gang's demands, over 600 patients' nude medical record photos were posted online. The plaintiffs' legal representation described the settlement as the largest of its kind.
STAT
SEPTEMBER 12, 2024
Lawmakers in Washington turned their focus to the Steward Health Care bankruptcy scandal on Thursday, even as patients, doctors, and regulators across eight states continue to struggle with the hospital chain’s financially starved facilities. Senators hoped to grill Steward chief executive Ralph de la Torre at the hearing in the Capitol but had to make do verbally attacking an empty chair.
Fierce Healthcare
SEPTEMBER 12, 2024
Steward Health Care CEO Ralph de la Torre, M.D., defied a subpoena to testify before Congress Thursday morning, leading heads of the investigating committee to promise civil enforcement and crimina | Despite receiving a Congressional subpoena, Ralph de la Torre, M.D., did not attend a Thursday morning hearing where he was scheduled to testify on the for-profit's financial struggles.
pharmaphorum
SEPTEMBER 12, 2024
Keir Starmer has promised the biggest 'reimagining' of the NHS in its history but said there will be no more funding without sweeping reforms
Pharmacy Times
SEPTEMBER 12, 2024
In a session at the 2024 World Conference on Lung Cancer, presenters highlight the most significant developments in local therapy for metastatic non–small cell lung cancer and advanced disease.
pharmaphorum
SEPTEMBER 12, 2024
Explore the ins and outs of Medicare drug pricing negotiations with Alice Valder Curran on this insightful podcast. Learn more about what comes next in this crucial healthcare sector.
Pharmacy Times
SEPTEMBER 12, 2024
As of May 2024, follow-up and exploratory analyses of MARIPOSA show improvements in outcomes for patients with EGRF-mutated non–small cell lung cancer (NSCLC).
Fierce Healthcare
SEPTEMBER 12, 2024
Iris Telehealth, a virtual-first behavioral health company, has launched two new technology-driven solutions, its new Virtual Clinic and back-end AI assistant, Iris Insights. | Iris Telehealth, a virtual-first behavioral healthcare managed services organization, unveiled two new technology offerings for health systems and community clinics to increase the efficiency of their behavior health practices.
Drug Topics
SEPTEMBER 12, 2024
Albert Dahan, MD, PhD, professor of anesthesiology at Leiden University Medical Center, talks about the first-in-class dual-NMR agonist cebranopadol.
Pharmaceutical Commerce
SEPTEMBER 12, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Pharmacy Times
SEPTEMBER 12, 2024
Tune into this episode of “Public Health Matters” to learn about the Unbiased Science podcast and how guest Jessica Steier, DrPH, PMP, aims to combat misinformation and disinformation, encouraging listeners to make evidence-based decisions.
Pharmaceutical Technology
SEPTEMBER 12, 2024
The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficacy in reducing blood glucose and weight.
The Checkup by Singlecare
SEPTEMBER 12, 2024
Hydroxyzine , also known by its brand names Vistaril and Atarax , is a first-generation antihistamine used to treat anxiety, insomnia, and allergy symptoms such as skin rash, hives, and itchiness. It has been FDA approved for use in the U.S. since 1957. Yet, there are no human studies establishing its safety during pregnancy. B ecause of the lack of data, some providers don’t prescribe hydroxyzine during pregnancy —especially during the first trimester and during labor.
Fierce Pharma
SEPTEMBER 12, 2024
By Dr. L. Alison McInnes and Jimmy Qian | We’re finally moving towards a causality-based nosology for psychiatry: specific symptoms with defined biological underpinnings can now be targeted by new therapies. But how do we bridge clinical development with real-world care? How do we ensure trial endpoints are synchronized with real-world measures, payer requirements, and clinical society guidelines?
Fierce Healthcare
SEPTEMBER 12, 2024
A new study suggests that major pharmacy benefit managers may be focusing on specific payer segments in a bid to maintain strong market share. | A new study suggests that major pharmacy benefit managers may be focusing on specific payer segments in a bid to maintain strong market share.
STAT
SEPTEMBER 12, 2024
Good morning! I’ve decided today is the day that I must tell you about my favorite Instagram account: poeticpuppets. It’s an account (run by a Teresa with no H, not me!) where puppets present you with some delicious poetry bites. Enjoy! A lifeline or a pharma handout? Either way, this program is set to expire There’s an obscure U.S. government voucher program due to sunset at the end of this month.
Fierce Healthcare
SEPTEMBER 12, 2024
Alignment Healthcare CEO John Kao gave strategic insights into how the insurer is thinking about market expansion and star ratings during the Baird Global Healthcare Conference on Wednesday. | Alignment Healthcare downplayed recent concerns surrounding star ratings cut points and stressed sizable long-term membership growth.
PharmaVoice
SEPTEMBER 12, 2024
Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.
Fierce Healthcare
SEPTEMBER 12, 2024
Elevance Health has entered into a deal to acquire Indiana University Health Plans, the company's Anthem Blue Cross unit announced this week. | Elevance Health has entered into a deal to acquire Indiana University Health Plans, the company's Anthem Blue Cross unit announced this week.
Expert insights. Personalized for you.
139 
Let's personalize your content